Tag: Incyte Corporation

Home / Incyte Corporation

Categories

Pemigatinib is approved for relapsed or refractory myeloid/lymphoid neoplasms with FGFR1 rearrangement

November 2022: Pemigatinib (Pemazyre, Incyte Corporation) has been licenced by the Food and Drug Administration for use in people with relapsed or refractory myeloid/lymphoid neoplasms (MLNs) that hav...
incyte-corporation

Scan the code